CRO Services (Phase IV) Partners
Phase 4 trials, also known as a post-approval studies, post-marketing surveillance trials, or real-world evidence (RWE) studies, are generally conducted after a Phase 3 trial is complete and a drug has received regulatory approval.
In a Phase 4 trial, side effects are studied over time in users of the drug after it has become commercially available. These trials allow the drug to be studied in a real-world population, which can be much more diverse and inclusive than the patients who took part in a Phase 3 clinical trial. The tools and technologies required for a Phase 4 trial are similar to those used in a Phase 3 trial. The conduct of these trials can also be managed by a CRO.
How can we help?
Looking for help with your Phase IV project? If you're searching for information or a supplier, let Clinical Leader lend you a hand.
Where Technology Meets Expertise. No other CRO is better prepared to support the future of clinical trials. Technology-led, user-focused and with expertise in oncology, cell & gene therapy, rare diseases, data science and analytics, we pioneered next generation trials. As the industry continues to undergo seismic change, our 20 years of expertise enables us to embrace radical disruption and transform the clinical trials landscape for the benefit of patients.
Now more than ever, the clinical development path is full of make-or-break data complexities and analytical challenges. As a pioneer in evidence generation, with deep expertise in advanced analytical solutions, we are uniquely equipped to unlock the value from increasingly complex data. Life Sciences companies count on Cytel to deliver exceptional insight, minimize trial risk and accelerate the development of promising new medicines that improve human life.
inSeption distinguishes people as the most impactful variable in the outsourcing equation. Our path-breaking model attracts biopharma companies who demand a partner that shares in their drive to conduct impeccable development and will provide quality and dependable clinical solutions. We offer full outsourcing, consulting services, and functional service provider (FSP) solutions.
IQVIA Biotech delivers flexible clinical development solutions designed to help biotech and emerging biopharma companies get treatments to patients. When you partner with our clinical team, you gain expertise from two decades of running clinical trials exclusively for biotech companies. We understand the unique challenges, hurdles, and opportunities you face. From strategy and trial design to execution, we draw on this experience to put together the right solution for you.
IQVIA Integrated Global Compliance offers a complete lifecycle approach that brings together safety, regulatory, quality, and medical information to transform how life sciences companies sustain compliance and how compliance functions perform better together.
By integrating services, technology, and analytics, we can help bring together disparate compliance functions, resulting in heightened patient safety, improved compliance performance, and proactive insights power by IQVIA Connected Intelligence.
Medidata Acorn AI is a Medidata company that represents the next horizon of the industry leader's 20-year mission of powering smarter treatments and healthier people. Acorn AI is designed to make data liquid across the entire lifecycle and to answer the most important questions in R&D and commercialization for customers. Built upon the Medidata platform comprising more than 20,000 trials and 5 million patients, Acorn AI products feature one of the industry's largest structured, standardized clinical trial data repository connected with real world, translational and other datasets.
OCT is the leading contract research organization in Russia. Since 2005, OCT's team has conducted over 300 clinical trials in 29 therapeutic areas in Eastern Europe and the CIS region. Our team of 150+ clinical professionals provides a full range of high-quality CRO services for Phase I-IV and BE studies, with therapeutic expertise in oncology, infectious disease, and all major therapeutic indications.
Precision ADVANCE is a collection of interconnected services and complementary teams uniquely focus on the complexities of clinical, regulatory, manufacturing, and commercial needs to successfully bring cell or gene therapies to market. Learn more about how we accelerate clinical development with Precision for Medicine, optimize next-gen manufacturing with Project Farma and drive commercial success with Precision Value & Health.
Premier Research recognizes that when an emerging biotech is built around a single asset, focus and flexibility are critical to success. And, since many of our customers require additional infrastructure, we fill in resourcing gaps to help their product reach the patient faster. We are a mid-size CRO and offer strategies that are customized for each program, with tailored processes designed to meet highly specific needs.
Veristat, a global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years' experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared over 100 marketing applications for approval with global regulatory authorities in the last 10 years alone.
Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval and real-world evidence, we provide world-class, full-service drug development services across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, general medicine, oncology and rare diseases. We never compromise on science or safety. We're never satisfied with the status quo. We're the Cure for the Common CRO.